EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy

In classical EGFR mutant non-small-cell lung cancer (NSCLC), EGFR tyrosine kinase inhibitor (TKI) therapy yields better outcomes than platinum-based chemotherapy. However, EGFR exon 20 insertion (ex20ins) NSCLC is relatively resistant to currently available EGFR TKIs. Though platinum-based chemother...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lung cancer 2022-03, Vol.23 (2), p.e148-e153
Hauptverfasser:	Shah, Manan P., Aredo, Jacqueline V., Padda, Sukhmani K., Ramchandran, Kavitha J., Wakelee, Heather A., Das, Millie S., Neal, Joel W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Drug Resistance, Neoplasm - drug effects EGFR ErbB Receptors - metabolism exon 20 insertion Follow-Up Studies Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Mutation Neoplasm Staging Non-small cell lung cancer Platinum - therapeutic use Retrospective Studies targeted therapy Treatment Outcome Tyrosine kinase inhibitor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!